Cyramza leads to median OS of 8.5 months in AFP-high HCC population

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III REACH-2 trial to treat hepatocellular carcinoma (HCC) in patients with high α fetoprotein (AFP)

Read the full 261 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE